Effects of antenatal indomethacin on ductus arteriosus early closure and on adverse outcomes in preterm neonates

Doni, Daniela; Paterlini, Giuseppe; Locatelli, Anna; Arnoldi, Sara; Magri, Maria Chiara; Bernasconi, Davide Paolo; Valsecchi, Maria Grazia; Tagliabue, Paolo

doi:10.1080/14767058.2018.1499091

Cited by 4 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indomethacin has also been used postpartum for the drug treatment of patent ductus arteriosus (PDA), but there are no data on the effect of prenatal exposure on postpartum ductal patency. While Doni D primarily focused on the relationship between prenatal indomethacin (AI) and postnatal ductus arteriosus patency, it has been concluded that PDA is more common at low gestational age, thus reducing the incidence of PDA could improve overall outcomes in preterm neonates [ 1 ]. Inhaled nitric oxide (iNO) therapy is useful for the treatment of managed respiratory stress and acute episodes of hypoxemia.…”

Section: Introductionmentioning

confidence: 99%

[Retracted] Profound Effect of Pulmonary Surfactant on the Treatment of Preterm Infants with Respiratory Distress Syndrome

Liu

Deng

2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Inherited diseases caused by dysfunction of pulmonary surfactant metabolism or surfactant dysfunction have recently been considered the underlying causes of neonatal and pediatric respiratory diseases. Respiratory distress syndrome in premature infants is a common respiratory disease in pediatrics. It is caused by underdeveloped lungs in infants and a lack of active substances on the surface of the alveoli, which leads to insufficiency of lung function, which can lead to difficulty breathing, increased heart rate, facial bruising, and more. Neonatal Respiratory Distress Syndrome is a very dangerous disease with a high mortality rate and a great threat to children’s lives and health. Therefore, enough attention and treatment should be caused in clinical practice. Natural pulmonary surfactant (PS) has achieved positive effects in the treatment of neonatal respiratory distress syndrome (RDS), reducing neonatal mortality, the application of mechanical ventilation, and the occurrence of late complications. To further explore the role of pulmonary surfactants in the treatment of neonatal respiratory distress syndrome, to analyze the best time to use PS to prevent RDS, this paper has selected premature infants with RDS received by the neonatal department of a hospital in a province from March 2019 to October 2020 to compare the efficacy of pulmonary surfactant (PS) in preterm infants with respiratory distress syndrome (RDS). The experiment has found that the average mechanical ventilation time (5.1 d) and oxygen therapy time (7.3 d) in the early group are shorter than the average mechanical ventilation time (6.4 d) and oxygen therapy time (10.6 d) in the late group. It has been demonstrated that early administration of pulmonary surfactant (PS) therapy is of great help in improving respiratory distress syndrome in premature infants.

show abstract

Section: Introductionmentioning

confidence: 99%